Across TCGA pan-cancer cohorts, KRTAP29-1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KRTAP29-1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KRTAP29-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRTAP29-1 is over-expressed in tumor, although a few such as PRAD and LIHC show the opposite, repressed pattern.

KIRC, LUSC, and LUAD are the cancer types where KRTAP29-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTAP29-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.053	<.001	8	view →
LUSC	All	All	+0.279	.002	4	view →
LUAD	All	All	+0.051	.012	2	view →
PRAD	All	All	−0.045	.008	2	view →
LIHC	All	II,III,IV	−0.015	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KRTAP29-1 RNA expression & survival · all KRTAP29-1 data types